JT
PRME icon

Jupiter Topco’s Prime Medicine PRME Stock Holding History

Jupiter Topco’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+60,900
New +$202K ﹤0.01% 2380

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jupiter Topco's PRME Position: Q2 2026 in Review

Jupiter Topco opened a new position in Prime Medicine (PRME) in Q2 2026: 60,900 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #2380 among its holdings.

174 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Jupiter Topco held 60,900 shares of Prime Medicine worth $224K as of Q2 2026.
  • Prime Medicine was a new Jupiter Topco position in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2380 holding.
  • 174 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.